11682 EL CAMINO REAL, SUITE 120, SAN DIEGO, CA
Outlines Strategic Priorities, including a Focused Commercial Strategy, and Reports Second Quarter 2026 Financial Results
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
Donn Casale Appointed CEO of ARS Pharmaceuticals; Richard Lowenthal Departs
Submission of Matters to a Vote of Security Holders
Reports First Quarter 2026 Financial Results and Corporate Update
Donn Casale Appointed President of ARS Pharmaceuticals, Inc.
Annual Report to Security Holders
Investor Presentation
Q2
Q1
FY 2025
Q3
FY 2024
Q3 amended
Registration Statement for Securities to be Offered to Employees
S-3ASR
Effectiveness Notice
Registration Statement for Securities Offered under a Shelf Registration
Additional Proxy Materials
Definitive Proxy Statement
Notice of Proposed Sale of Securities
Initial Statement of Beneficial Ownership
Schedule 13G - Ownership Report
Amended Schedule 13D - Ownership Report
Submission Upload
Correspondence